Bioventix plc

(“Bioventix” or “the Company”)

Director Dealing

 

Bioventix plc (BVXP), a UK company specialising in the development and commercial supply of high-affinity monoclonal antibodies for applications in clinical diagnostics, announces that the Company was notified on 22 November 2022 that on 21 November 2022 Bruce Hiscock, Chief Financial Officer of the Company, purchased a total of 50 ordinary shares of 5 pence each in the Company (“Ordinary Shares”), at an average price of 3,724 pence per Ordinary Share (the “Purchase”). The Ordinary Shares were purchased under a dividend reinvestment plan (“DRIP”).

 

Following the Purchase, Bruce Hiscock has a beneficial interest in 750 Ordinary Shares, representing approximately 0.01 per cent. of the issued share capital of the Company.

 

The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further details.

 

 

For further information please contact:

Bioventix plc

Peter Harrison

 

Chief Executive Officer

Tel: 01252 728 001
     
finnCap Ltd

Geoff Nash/Simon Hicks

Alice Lane

 

Corporate Finance

ECM

Tel: 020 7220 0500

 

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

 

1 Details of the person discharging managerial responsibilities / person closely associated
a) Name Bruce Hiscock
2. Reason for the Notification
a) Position/status Chief Financial Officer
b) Initial notification/Amendment Initial notification
3. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a) Name Bioventix Plc
b) LEI 213800225MHX7LZQY108
4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a) Description of the Financial instrument, type of instrument Ordinary Shares of 5 pence each
Identification code GB00B4QVDF07
b) Nature of the transaction Purchase of Ordinary Shares
c) Price(s) and volume(s) 50 Ordinary Shares

3,724 pence

d) Aggregated information:

 

·     Aggregated volume

 

·     Price

Purchase of 50 Ordinary Shares at 3,724 pence each
e) Date of the transaction 21 November 2022
f) Place of the transaction London Stock Exchange, AIM Market (XLON)

 

Bioventix plc (BVXP), a UK company specialising in the development and commercial supply of high-affinity monoclonal antibodies for applications in clinical diagnostics, confirms that its Annual Report and Accounts for the year ended 30 June 2022 and the Notice of Annual General Meeting (“AGM”) has been posted to shareholders.

A PDF version of the 30 June 2022 Annual Report can be downloaded here.

Notice of AGM to be held 8th December 2022 can be found here and proxy forms available here.

The AGM will be held at Farnham Castle, Farnham, Surrey, GU9 0AG at 2.00 p.m. on 8 December 2022.

The Board continues to monitor the situation surrounding COVID-19 and the advice from the Government on public gatherings. If the Government’s guidance changes at any point prior to the AGM, such that shareholders are unable to attend in person, the Company will update shareholders through an announcement to the London Stock Exchange and on the Company’s website. In light of this uncertainty, the Board strongly encourages shareholders to submit a proxy vote in advance of the AGM and to appoint the Chairman of the AGM as their proxy, rather than a named person who, if circumstances change, may not the able to attend the AGM.

 

For further information please contact:

Bioventix plc

Peter Harrison

Bruce Hiscock

 

Chief Executive Officer

Chief Financial Officer

Tel: 01252 728 001
finnCap Ltd

Geoff Nash/Simon Hicks

Alice Lane

 

Corporate Finance

ECM

Tel: 020 7220 0500

 

About Bioventix plc:

Bioventix (www.bioventix.com) specialises in the development and commercial supply of high-affinity monoclonal antibodies with a primary focus on their application in clinical diagnostics, such as in automated immunoassays used in blood testing. The antibodies created at Bioventix are generated in sheep and are of particular benefit where the target is present at low concentration and where conventional monoclonal or polyclonal antibodies have failed to produce a suitable reagent. Bioventix currently offers a portfolio of antibodies to customers for both commercial use and R&D purposes, for the diagnosis or monitoring of a broad range of conditions, including heart disease, cancer, fertility, thyroid function and drug abuse. Bioventix currently supplies antibody products and services to the majority of multinational clinical diagnostics companies. Bioventix is based in Farnham, UK and its shares are traded on AIM under the symbol BVXP.